Prediction of response to neoadjuvant chemotherapy by MammaTyper® across breast cancer subtypes: A retrospective cross-sectional study
Francesco Schettini(Target (United States)), Daniele Generali(University of Trieste), Silvana Saracchini(Centro di Riferimento Oncologico), Ilaria Specogna(Azienda Ospedaliera Santa Maria Degli Angeli), Mark Laible(BioNTech (Germany)), Anna Bassini(Azienda Ospedaliera Santa Maria Degli Angeli), Manuela Bertola, Sergio Aguggini(Istituti Ospitalieri di Cremona), Ralph M. Wirtz(Siemens Healthcare (Germany)), Richard Tancredi(Istituti Ospitalieri di Cremona), Carla Strina(Istituti Ospitalieri di Cremona), Uğur Şahin(Johannes Gutenberg University Mainz), Elvia Micheli(Azienda Ospedaliera Santa Maria Degli Angeli), Wally Marus(Azienda Ospedaliera Santa Maria Degli Angeli), Elena Fiorio(University of Verona), Manuela Milani(Humanitas University), Sandro Sulfaro(Azienda Ospedaliera Santa Maria Degli Angeli), Serena Corsetti(Centro di Riferimento Oncologico)
Cited by 5
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
mRNA-based therapeutics — developing a new class of drugs
|Nature Reviews Drug Discovery|2014|2.4k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k